The compliance and its affecting factors with treatment guideline recommendations of chronic HBV infection: A long-term follow-up cohort study.
Chang-hao ZHU,Yuan-kai WU,Xiang-yong LI,Guo-li LIN,Yu-sheng JIE,Fang-ji YANG,Yu-tian. CHONG
DOI: https://doi.org/10.3969/j.issn.1001-9448.2016.23.030
2016-01-01
Abstract:Objective To comprehensively evaluate the compliance and its affecting factors with treatment guide -line recommendations of chronic HBV infection .Methods A prospective analysis was conducted on 2328 outpatients with chronic HBV infection .The personal data of each patient were collected in detail .Each patient was required to return visit every six months as the guideline recommends .Those who could achieve the target were defined as good compliance , and those who couldn′t as poor compliance .Logistic regression analysis was used to screen the risk factors of poor compliance . Results The average follow-up duration was 3.0 years.The demographic characteristics (gender, address, family his-tory of HBV infection, et al.), baseline data (TB, HBV DNA), progression during the therapy and last time data (HB-sAg lost, progression to HCC, TB, HBeAg, et al.) were compared between the 2 groups.The age, family history of HCC, worse baseline data (high level of ALT, AST, HBeAg positive, et al.), better outcome of therapy (low level of ALT, AST, HBV DNA) and have NA ( s) therapy resulted in better compliance .And patients with good compliance showed higher level of ALT normality, complete viral response (CVR), HBeAg seroconversion and viral breakthrough . Multivariate logistic regression analysis showed family history of HCC , baseline HBV DNA level , baseline HBeAg stage , last time ALT level, last time HBV DNA level, and NA(s) therapy were independent risk factors for compliance of chron-ic HBV infection.Conclusion Patients with family history of HCC, high level of baseline HBV DNA, baseline HBeAg positive, high level of last time ALT and HBV DNA and without NA (s) therapy are more likely to have poor compliance to chronic hepatitis B treatment guideline recommendations .